<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00980616</url>
  </required_header>
  <id_info>
    <org_study_id>CHU-0056</org_study_id>
    <nct_id>NCT00980616</nct_id>
  </id_info>
  <brief_title>Use of Local Analgesia With Epinephrine During Total Hip Arthroplasty (THA)</brief_title>
  <official_title>Effect of the Injection of Local Analgesia With Epinephrine During Total Hip Arthroplasty on the Blood Losses Per and Operatively.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <brief_summary>
    <textblock>
      The aim is to determine if the use of infiltration with an adrenalin solution in the
      operative field of Total Hip Arthroplasty (THA), allays a significant reduction of the
      cumulated volume of bleeding (pre and post operative) without increasing the per and post
      operative risks. At the same time, the effect on the post operational pains is evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective randomized study compares a population receiving a local anaesthetic
      (ropivacaine, adrenalin and physiological serum) in the operative field to a population
      undergoing a standard protocol.

      The cumulated volume of bleeding per and post operative are recorded and complete blood count
      (CBC).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>measuring volume of cumulated bleeding per and post operative and analyse of complete blood count (CBC)</measure>
    <time_frame>pre and post operative</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Womac score pre operative, at 3 months and at 12 months</measure>
    <time_frame>at 3 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual analogue pain score (VAS) during hospitalisation</measure>
    <time_frame>at 3 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consumption of analgesics</measure>
    <time_frame>at 3 months and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Arthroplasty, Replacement, Hip</condition>
  <arm_group>
    <arm_group_label>Ropivacaine, serum, adrenalin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>235 mg of ropivacaine, 5 ml physical serum and 0.5 mg of adrenalin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No infiltration</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>B: no infiltration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ropivacaine, physical serum and adrenalin</intervention_name>
    <description>A: experimental group: 235 mg of ropivacaine, 5 ml physical serum and 0.5 mg of adrenalin</description>
    <arm_group_label>Ropivacaine, serum, adrenalin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary total hip arthroplasty

          -  Age between 50 and 85

        Exclusion Criteria:

          -  fracture of the femoral neck

          -  patients with contraindications for local anaesthesia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephane Descamps, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand (orthopaedic surgery)</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2009</study_first_submitted>
  <study_first_submitted_qc>September 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2009</study_first_posted>
  <last_update_submitted>March 26, 2012</last_update_submitted>
  <last_update_submitted_qc>March 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Arthroplasty, hip</keyword>
  <keyword>blood losses</keyword>
  <keyword>pain</keyword>
  <keyword>local analgesia</keyword>
  <keyword>epinephrine</keyword>
  <keyword>Primary total hip arthroplasty</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

